Stockscreener 앱 받기
1.16
0.00%
0.00
시간 외 거래:
1.15
-0.01
-0.86%
전일 마감가:
$1.16
열려 있는:
$1.15
하루 거래량:
98,725
Relative Volume:
0.09
시가총액:
$4.50M
수익:
$35.49M
순이익/손실:
$-6.04M
주가수익비율:
-0.0891
EPS:
-13.0191
순현금흐름:
$-6.42M
1주 성능:
+0.87%
1개월 성능:
-33.71%
6개월 성능:
-90.17%
1년 성능:
-91.83%
1일 변동 폭
$1.14
$1.17
1주일 범위
$1.03
$1.23
52주 변동 폭
$1.03
$24.30
Sunshine Biopharma Inc Stock (SBFM) Company Profile
명칭
Sunshine Biopharma Inc
전화
954-330-0684
주소
333 LAS OLAS WAY, FORT LAUDERDALE
Compare SBFM vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
1.16 | 4.50M | 35.49M | -6.04M | -6.42M | -13.02 |
TAK
Takeda Pharmaceutical Co Adr
|
18.18 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.00 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.34 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.73 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
513.12 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Sunshine Biopharma Inc 주식(SBFM)의 최신 뉴스
Sunshine Biopharma wins Canadian approval for generic Enalapril tablets - Bitget
SBFM Looks 55.2% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
BRIEF-Sunshine Biopharma Receives Canadian Regulatory Approval For Enalapril - Bitget
Sunshine Biopharma receives Canadian approval for generic enalapril - Investing.com
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market - Eagle-Tribune
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug - Yahoo Finance
Sunshine (SBFM) Quarterly Performance Check: The Company Lists Its Latest Available Figures in the Reported Period; Session Reaction: The Stock Ends Up 1.79% in the Latest ReadingEarnings Momentum Score - vinanet.vn
101,973 Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-AUG-2026. - marketscreener.com
Sunshine Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
SBFM Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.25 Per-Share Loss as Shares Slip 4.17%Revenue Warning Signal - vinanet.vn
SBFM Q1 2026 Earnings: Reported Loss of $0.25 Per Share as Stock Declines 4.17%Pre-Earnings Setup - Vinanet
SBFM Q1 2026 Earnings: Net Loss of -$0.25 Per Share as Pre-Revenue Oncology Developer Presses OnForward Guidance Trends - vinanet.vn
L1 Capital (SBFM) discloses 4.99% Sunshine Biopharma stake plus large warrant position - Stock Titan
Sunshine Biopharma Inc (NASDAQ: SBFM) Share Price, SBFM Stock News, SBFM Share Price & Updates - kalkine.ca
Sunshine Biopharma (SBFM) investors cap warrant-driven stake at 9.99% - Stock Titan
Sunshine Biopharma (SBFM) Earnings Date and Reports 2026 - MarketBeat
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market - The Lawton Constitution
Sunshine Biopharma (SBFM) Holds Gains at $1.23 as Stock Stays Rangebound Between Key LevelsActive ETF Flow - dars.gov.et
SBFM Stock Holds Support As Traders Eye Next Move - timothysykes.com
SBFM Stock Holds Support As Sunshine Biopharma Tightens Cash Control - StocksToTrade
SBFM Stock Holds Range As Traders Weigh Weak Margins - timothysykes.com
SBFM Stock Slides As Traders Focus On Cash Runway And Volatility - StocksToTrade
SBFM Stock Pops As Health Canada Greenlights New Generics - StocksToTrade
Amoxicillin Market Estimated at $4.9B as Canada Shipments Begin - Stock Titan
Sunshine Biopharma Inc. Revenue Breakdown – NASDAQ:SBFMW - TradingView
SBFM Looks 84.2% Undervalued on GF Value™ Despite Distressed Fun - GuruFocus
Sunshine Biopharma receives Canadian approval for generic dienogest By Investing.com - Investing.com Nigeria
Sunshine Biopharma receives Canadian approval for generic dienogest - Investing.com
Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval - Stock Titan
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval - Benzinga
SBFM Q2'26 Earnings: EPS estimate is (1.20) USD - TradingView
Sunshine Biopharma wins Canadian approval for generic Dienogest tablets - Bitget
Sunshine Biopharma cuts exercise price of outstanding Series B warrants to $1.22 - Bitget
Sunshine Biopharma Inc. (SBFM) Q1 2026 Earnings: Loss Per Share Widens as Revenue Remains ZeroPeak Earnings Alert - dars.gov.et
SBFM Looks 79.1% Undervalued on GF Value™ Amid Challenging Finan - GuruFocus
Sunshine Biopharma receives Canadian approval for ondansetron - Investing.com
Sunshine Biopharma receives Canadian approval for ondansetron By Investing.com - Investing.com Canada
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting - New Castle News
Sunshine Biopharma adds oral disintegrating tablets for chemotherapy nausea - Stock Titan
Sunshine Biopharma Inc (SBFM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SBFM|Sunshine Biopharma Inc|Price:1.696| - TradingKey
Sunshine Biopharma Inc (SBFM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SBFM|Sunshine Biopharma Inc|Price:1.230|Chg%:-0.170 - TradingKey
SBFM Q1 2026 Earnings: Net Loss Widens as Pre-Revenue Biotech Focuses on R&D Pipeline - vinanet.vn
Sunshine Biopharma Inc. (SBFM) Q1 2026 Earnings: Continued R&D Investment Drives Net Loss, No Revenue ReportedEarnings Outlook Update - dars.gov.et
Sunshine Biopharma Inc. Revenue Breakdown – NASDAQ:SBFM - TradingView
Sunshine Biopharma Inc. Revenue Breakdown – BOATS:SBFMW - TradingView
Sunshine Biopharma Inc (SBFM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sunshine Biopharma Inc. (SBFM) Q1 2026 Earnings: Continued R&D Investment Leads to Net Loss Amid No Revenue - dars.gov.et
Price to sales forward of Sunshine Biopharma Inc. – NASDAQ:SBFMW - TradingView
SBFM Q1 2026 Earnings: Net Loss Per Share of $0.25 as Pre-Revenue Biopharma Advances PipelineGuidance Update - vinanet.vn
Sunshine Biopharma Inc (SBFM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
0.24%
자본화:
|
볼륨(24시간):